Autobio Diagnostics Co., Ltd. (SHA:603658)
China · Delayed Price · Currency is CNY 33.57
-0.34 (-1.00%)
Apr 24, 2026, 3:00 PM CST
Autobio Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,223 | 4,226 | 4,389 | 4,368 | 4,366 | 3,686 |
Other Revenue | - | - | 81.98 | 76.05 | 75.76 | 79.82 |
| 4,223 | 4,226 | 4,471 | 4,444 | 4,442 | 3,766 | |
Revenue Growth (YoY) | -3.55% | -5.47% | 0.62% | 0.05% | 17.94% | 26.45% |
Cost of Revenue | 1,435 | 1,452 | 1,582 | 1,612 | 1,844 | 1,545 |
Gross Profit | 2,787 | 2,774 | 2,889 | 2,832 | 2,597 | 2,221 |
Selling, General & Admin | 1,107 | 1,092 | 953.05 | 920.21 | 857.11 | 757.02 |
Research & Development | 558.67 | 555.12 | 731.93 | 656.13 | 568.48 | 480.96 |
Other Operating Expenses | -12.16 | -26.97 | -3.25 | 28.05 | 28.24 | 13.73 |
Operating Expenses | 1,653 | 1,620 | 1,737 | 1,626 | 1,471 | 1,267 |
Operating Income | 1,134 | 1,154 | 1,152 | 1,206 | 1,126 | 954.28 |
Interest Expense | - | - | -22.28 | -24.54 | -21.23 | -12.68 |
Interest & Investment Income | 100.93 | 104.51 | 112.84 | 144.76 | 135.09 | 116.43 |
Currency Exchange Gain (Loss) | - | - | 0.63 | 1.19 | 7.47 | -9.65 |
Other Non Operating Income (Expenses) | -31.32 | -13.51 | -2.08 | -2.9 | -5.18 | 0.77 |
EBT Excluding Unusual Items | 1,203 | 1,245 | 1,241 | 1,325 | 1,242 | 1,049 |
Gain (Loss) on Sale of Investments | -2.94 | -3.5 | 3.61 | 0.58 | - | 0.03 |
Gain (Loss) on Sale of Assets | 0.6 | 0.64 | -12.2 | -2.78 | -1.72 | -1.17 |
Asset Writedown | -18.41 | -19.71 | -52.75 | - | - | - |
Other Unusual Items | - | - | 109.07 | 39.95 | 53.06 | 17.54 |
Pretax Income | 1,183 | 1,223 | 1,289 | 1,363 | 1,294 | 1,066 |
Income Tax Expense | 130.17 | 136.38 | 89.82 | 138.41 | 105.03 | 85.69 |
Earnings From Continuing Operations | 1,052 | 1,086 | 1,199 | 1,224 | 1,189 | 979.86 |
Minority Interest in Earnings | -17.86 | -18.37 | -4.78 | -6.69 | -21.25 | -6.19 |
Net Income | 1,035 | 1,068 | 1,194 | 1,217 | 1,167 | 973.66 |
Net Income to Common | 1,035 | 1,068 | 1,194 | 1,217 | 1,167 | 973.66 |
Net Income Growth | -9.26% | -10.59% | -1.89% | 4.28% | 19.90% | 30.20% |
Shares Outstanding (Basic) | 572 | 571 | 577 | 580 | 584 | 587 |
Shares Outstanding (Diluted) | 572 | 571 | 577 | 580 | 584 | 587 |
Shares Change (YoY) | -0.71% | -1.02% | -0.47% | -0.68% | -0.48% | 5.10% |
EPS (Basic) | 1.81 | 1.87 | 2.07 | 2.10 | 2.00 | 1.66 |
EPS (Diluted) | 1.81 | 1.87 | 2.07 | 2.10 | 2.00 | 1.66 |
EPS Growth | -8.61% | -9.66% | -1.43% | 5.00% | 20.48% | 23.88% |
Free Cash Flow | 731.25 | 737.38 | 644.88 | 569.44 | 620.1 | 395.39 |
Free Cash Flow Per Share | 1.28 | 1.29 | 1.12 | 0.98 | 1.06 | 0.67 |
Dividend Per Share | - | - | 1.260 | 1.052 | 0.800 | 0.750 |
Dividend Growth | - | - | 19.76% | 31.51% | 6.67% | 14.71% |
Gross Margin | 66.01% | 65.64% | 64.61% | 63.73% | 58.47% | 58.98% |
Operating Margin | 26.85% | 27.31% | 25.77% | 27.15% | 25.36% | 25.34% |
Profit Margin | 24.50% | 25.27% | 26.71% | 27.40% | 26.28% | 25.86% |
Free Cash Flow Margin | 17.32% | 17.45% | 14.42% | 12.81% | 13.96% | 10.50% |
EBITDA | 1,588 | 1,610 | 1,616 | 1,642 | 1,544 | 1,340 |
EBITDA Margin | 37.60% | 38.10% | 36.15% | 36.96% | 34.76% | 35.59% |
D&A For EBITDA | 454 | 456.04 | 464.2 | 436.1 | 417.56 | 385.93 |
EBIT | 1,134 | 1,154 | 1,152 | 1,206 | 1,126 | 954.28 |
EBIT Margin | 26.85% | 27.31% | 25.77% | 27.15% | 25.36% | 25.34% |
Effective Tax Rate | 11.01% | 11.15% | 6.97% | 10.16% | 8.12% | 8.04% |
Revenue as Reported | - | - | 4,471 | 4,444 | 4,442 | 3,766 |
Advertising Expenses | - | - | 54.35 | 55.79 | 41.4 | 45.1 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.